Anderson’s Atlas of Hematology

Index

Note: Page numbers in italics followed by f denote figures; those followed by t denote tables.

A with minimal differentiation congenital pure red blood cell
(M0), 363–364, 363f 364f aplasia, 246–247, 246f 247f
Abnormal promyelocyte, 90–91, 90f 471–472, 471f 472f
Acanthocyte, 27, 27f endocrine diseases, 324–325, 324f
Acanthocytosis, hereditary, 297–298, with mutated CEBPA, 469–470, 325f
469f 470f
297f 298f erythropoietic porphyria (Gunther’s
Acid elution (Kleihauer-Betke stain), with mutated NPM1, 467–468, 467f Disease), 217–218, 217f
468f 218f
188, 188f
Acid phosphatase reaction with recurrent genetic erythropoietic protoporphyria,
abnormalities, 446–470 219–220, 219f 220f
with tartrate inhibition (TRAP),
176–177, 176f with t(1;22)(p13;q13); RBM15- Fanconi’s anemia, 248–249, 248f
MKL1, 464–466, 464f 466f 249f
without tartrate inhibition, 178,
178f with t(6;9)(p23;q34); DEK-NUP214, folic acid deficiency, 230–232, 230f
459–460, 459f 460f 232f
Acquired aplastic anemia, 240–242,
240f 242f with t(8;21)(q22; q22); RUNX1- glucose-6-phosphate
RUNX1T1, 446–448, 446f dehydrogenase deficiency,
Acute basophilic leukemia, 492–493, 447f 294–296, 294f 296f
492f 493f
with t(9;11)(p22;q23); MLLT3-MLL, hemoglobin constant spring
Acute blood loss, 317–319, 318f, 456–458, 456f 457f 458f syndrome, 267–268, 267f
319f 268f
Acute myelomonocytic leukemia
Acute erythroid leukemia, 484–488, (M4), 373–374, 373f 374f hemoglobin lepore syndrome,
484f 486f 488f 478–479, 478f 479f 275–277, 275f 277f

Acute megakaryoblastic leukemia, Acute myelomonocytic leukemia hemolytic anemias, 291–315
489–491, 489f 491f with increased bone marrow hereditary acanthocytosis, 297–298,
eosinophils (M4eo), 375–376,
Acute megakaryoblastic leukemia 375f 297f 298f
(M7), 385–386, 385f hereditary elliptocytosis, 299–301,
Acute panmyelosis with myelofibrosis
Acute monoblastic leukemia (M5a), (APMF), 494–496, 494f 496f 299f 301f
377–378, 377f 378f, 480–483, hereditary persistence of fetal
480f 481f 483f Acute promyelocytic leukemia
with t(15;17)(q22;q12); PML-RARA, hemoglobin, 278–280, 278f
Acute monocytic leukemia (M5b), 452–455, 452f 453f 454f 280f
379–380, 379f 380f 480f 455f hereditary spherocytosis, 302–303,
481f 483f 302f 303f
Acute promyelocytic leukemia– hereditary stomatocytosis, 304–305,
Acute myeloid leukemia (AML) (WHO) hypergranular (M3), 369–370, 304f 305f
acute basophilic leukemia, 492–493, 369f hypoproliferative anemias, 237–251
492f 493f immune hemolytic anemia,
acute erythroid leukemia, 484–488, Acute promyelocytic leukemia– 306–307, 306f 307f
484f 486f 488f microgranular variant (M3v), iron deficiency anemia, 221–223,
acute megakaryoblastic leukemia, 371–372, 371f 372f 221f 223f
489–491, 489f 491f lead intoxication (plumbism),
acute monoblastic leukemia, Adolescent cellularity, normal, 156, 224–225, 224f 225f
480–483, 480f 481f 483f 156f liver disease, 326–327, 326f 327f
acute monocytic leukemia, megaloblastic anemias, 229–235
480–483, 480f 481f 483f Adult cellularity microangiopathic hemolytic
acute panmyelosis with adult hypercellularity, 159, 159f anemia, 308–309, 308f 309f
myelofibrosis (APMF), adult hypocellularity, 158, 158f nonimmune hemolytic anemia,
494–496, 494f 496f normal, 154, 154f 310–311, 310f 311f
acute promyelocytic leukemia, with normal elderly cellularity, 155, 155f paroxysmal nocturnal
t(15;17)(q22;q12); PML- hemoglobinuria, 312–313,
RARA, 452–455, 452f 453f Adult T-cell leukemia/lymphoma, 312f 313f
454f 455f 536–537, 536f 537f pure red cell aplasia, 250–251,
associated with down syndrome, 250f 251f
497–498, 497f 498f Agglutination, 25, 25f pyruvate kinase deficiency,
with inv(16)(p13.1;q22) or t(16;16) Alder-Reilly bodies, 77, 77f 314–315, 314f 315f
(p13.1;q22); CBFB-MYH11, Anemia sideroblastic anemia, 226–228,
449–451, 449f 450f 451f 226f 228f
with inv(3)(q21;q26.2) or t(3;3) acquired aplastic anemia, 240–242, systemic disorders, anemias
(q21;q26.2); RPN1-EVl1, 240f 242f associated with, 321–329
461–463, 461f 463f systemic lupus erythematosus,
without maturation (M1), of acute blood loss, 317–319, 318f 328–329, 328f 329f
365–366, 365f 319f a thalassemia (3 gene deletion),
without maturation, 473–474, 473f 256–257, 256f 257f
474f caused by myelophthisis, 238–239, a thalassemia (4 gene deletion),
with maturation, 367–368, 367f 238f 239f 254–255, 254f 255f
475–477, 475f 477f
of chronic disease, 214–216, 214f 583
216f

chronic renal disease, 332–323,
322f 323f

cold agglutinin disease, 292–293,
292f 293f

congenital dyserythropoietic
anemia, 243–245, 243f 245f

66485457-66485438 www.ketabpezeshki.com

66485457-66485438

www.ketabpezeshki.com

584 Index

Anemia (continued) Chédiak-Higashi granules, 79, 79f D
a thalassemia minor and silent Children
carrier, 258–259, 258f 259f Dacryocyte (teardrop cell), 29, 29f
b thalassemia, 260–263, 260f 261f normal adolescent cellularity, 156, Degmacyte (bite cell), 30, 30f
263f 156f Diamond-Blackfan anemia, 246–247,
vitamin B12 deficiency, 233–235,
233f 235f normal newborn cellularity, 157, 246f 247f
157f Diffuse large B-cell lymphoma,
Atypical chronic myeloid leukemia
(aCML), 420–422, 420f 422f Chronic disease, anemia of, 214–216, 528–529, 528f 529f
214f 216f Dimorphic cells, 42, 42f
Auer rods, 78, 78f Döhle body, 80, 80f
Chronic eosinophilic leukemia, Drepanocyte (sickle cell), 31, 31f
B 409–411, 409f Dutcher body, 123, 123f
Dyserythropoiesis, 54, 54f
B-cell prolymphocytic leukemia, Chronic granulomatous disease, Dysgranulopoiesis, 92, 92f
511–512, 511f 512f 336–337, 336f 337f
E
B lymphoblastic leukemia/lymphoma, Chronic lymphocytic leukemia
500–503, 500f 501f 503f lymphocyte, 107, 107f Early myelocyte, late myelocyte and,
150, 150f
Babesiosis, 554–555, 554f 555f Chronic lymphocytic leukemia/
Bands, 66–68, 66f 67f 68f small lymphocytic lymphoma, Echinocyte (burr cell), 32, 32f
508–510, 508f 510f Elderly, the, normal elderly cellularity,
giant, 93, 93f
Basophilia, 332–333, 332f 333f Chronic myelogenous leukemia, 155, 155f
Basophilic band, 68, 68f 396–399, 397f Elliptocytosis, hereditary, 299–301,
Basophilic megaloblast (megaloblastic
Chronic myelomonocytic leukemia 299f 301f
prorubricyte), 13, 13f (CMML), 416–419, 416f 417f Endocrine diseases, 324–325, 324f 325f
Basophilic metamyelocyte, 65, 65f 419f Eosinophilia, 338–339, 338f 339f
Basophilic myelocyte, 62, 62f Eosinophilic band, 67, 67f
Basophilic normoblast Chronic neutrophilic leukemia, Eosinophilic metamyelocyte, 64, 64f
400–402, 400, 400f 402f Eosinophilic myelocyte, 61, 61f
and myeloblast, 142, 142f Eosinophils, 57, 57f 70, 70f
Basophilic normoblast (prorubricyte), Chronic renal disease, 332–323, 322f Erythrocyte series, 4, 4f
323f Erythrocytosis, 205–212
6, 6f
Basophilic stippling (punctate Classical Hodgkin lymphoma, polycythemia vera, 206–208, 206f
542–543, 542f 543f 208f
basophilia), 45, 45f
Basophils, 57, 57f 71, 71f Cleaved cell (butt cell), 102, 102f relative polycythemia (Gaisböck
BCR-ABL1 positive, 396–399 Codocyte (target cell), 28, 28f Syndrome), 209–210, 209f
Bilobed plasma cell, 122, 112f Cold agglutinin disease, 292–293, 210f
Blood cells
292f 293f secondary polycythemia, 211–212,
red, 3–54 Comparison of cells, 139–151 211f 212f
white, 55–126 Congenital dyserythropoietic anemia,
Bone marrow Erythroleukemia (M6a), 381–382,
cells of the reticuloendothelial 243–245, 243f 245f 381f 382f
Congenital pure red blood cell aplasia
system, 165–170 Erythropoiesis, 160, 160f
cellularity, 153–163 (Diamond-Blackfan anemia), Erythropoietic porphyria (Gunther’s
Borreliosis, 556–557, 556f 557f 246–247, 246f 247f
Burkitt lymphoma, 391–392, 391f Cytochemical stains Disease), 217–218, 217f 218f
acid elution (Kleihauer-Betke stain), Erythropoietic protoporphyria,
530–531, 530f 531f
Burr cell, 32, 32f 188, 188f 219–220, 219f 220f
Butt cell, 102, 102f acid phosphatase reaction, 176–178, Essential thrombocythemia (ET),

C 176f 178f 406–408, 406f 408f
combined esterase reaction, 185, Esterase reaction, combined, 185, 185f
Cabot ring, 46, 46f Esterase reaction, nonspecific
Candidiasis, 558–559, 558f 559f 185f
Cells, comparison of, 139–151 iron stain—Prussian blue reaction, with fluoride inhibition, 179–180,
Cellularity 179f
186–187, 186f
adult hypercellularity, 159, 159f leukocyte alkaline phosphatase without fluoride inhibition,
adult hypocellularity, 158, 158f 181–182, 181f
erythropoiesis, 160, 160f stain, 189–190, 189f
granulopoiesis, 161, 161f new methylene blue and brilliant Esterase reaction, specific, 183–184,
lymphopoiesis, 162, 162f 183f
megakaryopoiesis, 163, 163f cresyl blue stains, 191,
normal, 154–163 191f F
normal adolescent cellularity, 156, nonspecific esterase reaction,
179–182, 179f 181f Faggot cell, 81, 81f
156f periodic acid-Schiff reaction, Fanconi’s anemia, 248–249, 248f 249f
normal adult cellularity, 154, 154f 192–193, 192f Fetal hemoglobin, hereditary
normal newborn cellularity, 157, peroxidase stain, 194–195, 194f
reticulin stain, 201, 201f persistence of, 278–280, 278f
157f specific esterase reaction, 183–184, 280f
Chédiak-Higashi anomaly, 334–335, 183f Filariasis, 560–561, 560f 561f
sudan black B stain, 196–197, Flaming plasma cell, 124, 124f
334f 335f 196f Fluoride inhibition
terminal deoxynucleotidyl nonspecific esterase reaction with,
transferase reaction,
198–199, 198f 179–180, 179f
toluidine blue stain, 200, 200f
Cytoplasmic inclusions, 77–86

66485457-66485438 www.ketabpezeshki.com

Index 585

nonspecific esterase reaction Heinz bodies, 47, 47f immune hemolytic anemia,
without, 181–182, 181f Hematologic disease associated with 306–307, 306f 307f

Folic acid deficiency, 230–232, 230f microorganisms, 553–571 microangiopathic hemolytic
232f babesiosis, 554–555, 554f 555f anemia, 308–309, 308f 309f
borreliosis, 556–557, 556f 557f
Follicular lymphoma, 524–525, 524f candidiasis, 558–559, 558f 559f nonimmune hemolytic anemia,
525f filariasis, 560–561, 560f 561f 310–311, 310f 311f
histoplasmosis, 562–563, 562f 563f
French American British (FAB) leishmaniasis, 564–565, 564f 565f paroxysmal nocturnal
classification, of leukemia, malaria, 566–567, 566f 567f hemoglobinuria, 312–313,
357–392 toxoplasmosis, 568–569, 568f 569f 312f 313f
trypanosomiasis, 570–571, 570f
acute megakaryoblastic leukemia pyruvate kinase deficiency,
(M7), 385–386, 385f 571f 314–315, 314f 315f
Hematologic disorders
acute monoblastic leukemia (M5a), Hereditary acanthocytosis, 297–298,
377–378, 377f 378f miscellaneous disorders, 545–581 297f 298f
red blood cell disorders, 205–329
acute monocytic leukemia (M5b), white blood cell disorders, 331–543 Hereditary elliptocytosis, 299–301,
379–380, 379f 380f Hematologic neoplasms, 393–394 299f 301f
Hemoglobin
acute myeloid leukemia without unstable hemoglobins, 288–289, Hereditary persistence of fetal
maturation (M1), hemoglobin, 278–280, 278f
365–366, 365f 288f 289f 280f
Hemoglobin C, 264–266, 264f 266f
acute myeloid leukemia with Hemoglobin C crystals, 48, 48f Hereditary spherocytosis, 302–303,
maturation (M2), 367–368, Hemoglobin constant spring 302f 303f
367f
syndrome, 267–268, 267f 268f Hereditary stomatocytosis, 304–305,
acute myeloid leukemia, with Hemoglobin D, 269–270, 269f 270f 304f 305f
minimal differentiation Hemoglobin E, 271–272, 271f 272f
(M0), 363–364, 363f 364f Hemoglobin E/b thalassemia, Histoplasmosis, 562–563, 562f 563f
Hodgkin lymphoma, 541–543, 542f
acute myelomonocytic leukemia 273–274, 273f 274f
(M4), 373–374, 373f 374f Hemoglobin H disease, 256–257, 543f
Howell-Jolly body, 51, 51f
acute myelomonocytic leukemia 256f 257f Hypersegmentation, 73, 74f
with increased bone Hemoglobin H inclusions, 49, 49f Hypochromic cells, 43, 43f
marrow eosinophils (M4eo), Hemoglobin lepore syndrome, Hypoproliferative anemias, 237–251
375–376, 375f
275–277, 275f 277f acquired aplastic anemia, 240–242,
acute promyelocytic leukemia– Hemoglobin S, 281–283, 281f 283f 240f 242f
hypergranular (M3), Hemoglobin S/C disease, 286–287,
369–370, 369f anemia caused by myelophthisis,
286f 287f 238–239, 238f 239f
acute promyelocytic leukemia– Hemoglobin S/b thalassemia,
microgranular variant (M3v), congenital dyserythropoietic
371–372, 371f 372f 284–285, 284f anemia, 243–245, 243f 245f
Hemoglobin SC crystals, 50, 50f
Burkitt type (L3), 391–392, 391f Hemoglobinopathies, 253–289 congenital pure red blood cell
erythroleukemia (M6a), 381–382, aplasia, 246–247, 246f 247f
hemoglobin C, 264–266, 264f 266f
381f 382f hemoglobin D, 269–270, 269f 270f Fanconi’s anemia, 248–249, 248f
of leukemia, 358–362, 358f 359f hemoglobin E, 271–272, 271f 272f 249f
hemoglobin E/b thalassemia,
360f 361f 362f pure red cell aplasia, 250–251,
precursor lymphoblastic leukemia 273–274, 273f 274f 250f 251f
hemoglobin S, 281–283, 281f 283f
(L1), 387–388, 387f hemoglobin S/C disease, 286–287, I
precursor lymphoblastic leukemia
286f 287f Immune hemolytic anemia, 306–307,
(L2), 389–390, 389f hemoglobin S/b thalassemia, 306f 307f
pure erythroid leukemia (M6b),
284–285, 284f Immunoblast, 103, 103f
383–384, 383f unstable hemoglobins, 288–289, Inclusions, 45–53

G 288f 289f abnormal plasma cells and, 122–126
Hemolytic anemias, 291–315 cytoplasmic, 77–86
Gaisböck Syndrome, 209–210, 209f Infectious mononucleosis, 340–341,
210f cold agglutinin disease, 292–293,
292f 293f 340f 341f
Gaucher cell, 168, 168f Iron deficiency anemia, 221–223,
Gaucher disease, 574–575, 574f 575f glucose-6-phosphate
Giant myelocytes, metamyelocytes, dehydrogenase deficiency, 221f 223f
294–296, 294f 296f Iron stain—Prussian blue reaction,
and bands, 93, 93f
Giant platelet, 133, 133f hereditary acanthocytosis, 297–298, 186–187, 186f
Glucose-6-phosphate dehydrogenase 297f 298f Iron-deficient basophilic normoblast

deficiency, 294–296, 294f 296f hereditary elliptocytosis, 299–301, (iron-deficient prorubricyte),
Granulocytes, malignant, 87–91 299f 301f 20, 20f
Granulopoiesis, 161, 161f Iron-deficient erythrocyte
Grape cell, 125, 125f hereditary spherocytosis, 302–303, (hypochromic/microcytic),
302f 303f 24, 24f
H Iron-deficient orthochromic
hereditary stomatocytosis, 304–305, normoblast (iron-deficient
Hairy cell, 108, 108f 304f 305f metarubricyte), 22, 22f
Hairy cell leukemia, 513–515, 513f Iron-deficient polychromatophilic
erythrocyte (reticulocyte), 23,
515f 23f

66485457-66485438 www.ketabpezeshki.com

586 Index

Iron-deficient polychromatophilic acute promyelocytic leukemia– Lymphocytosis, 342–346, 342f
normoblast (iron-deficient microgranular variant (M3v), 346f
rubricyte), 21, 21f 371–372, 371f 372f
Lymphoma cells, 113–117
Iron-deficient pronormoblast (iron- adult T-cell leukemia/lymphoma, Lymphomas
deficient rubriblast), 19, 19f 536–537, 536f 537f
adult T-cell leukemia/lymphoma,
Iron-deficient series, 18–24, 18f atypical chronic myeloid leukemia 536–537, 536f 537f
(aCML), 420–422, 420f 422f
J B lymphoblastic leukemia/
B-cell prolymphocytic leukemia, lymphoma, 500–503, 500f
Juvenile myelomonocytic leukemia 511–512, 511f 512f 501f 503f
( JMML), 423–425, 423f 425f
B lymphoblastic leukemia/ Burkitt lymphoma, 391–392, 391f
K lymphoma, 500–503, 500f 530–531, 530f 531f
501f 503f
Keratocyte (horn cell), 33, 33f classical Hodgkin lymphoma,
Kleihauer-Betke stain, 188, 188f Burkitt lymphoma, (L3), 391–392, 542–543, 542f 543f
Knizocyte (pinch cell), 34, 34f 391f
diffuse large B-cell lymphoma,
L chronic eosinophilic leukemia, 528–529, 528f 529f
409–411, 409f
L1 lymphoblast, 109, 109f follicular lymphoma, 524–525, 524f
L2 lymphoblast, 110, 110f chronic lymphocytic leukemia/small 525f
L3 lymphoblast, 111, 111f lymphocytic lymphoma,
Large granular lymphocyte, 104, 104f 508–510, 508f 510f Hodgkin lymphoma, 541–543, 542f
Large lymphocyte, 105, 105f 543f
Large megakaryocyte, 134, 134f chronic myelogenous leukemia,
Large mononuclear megakaryocyte, 396–399, 397f lymphoblastic lymphoma cell, 113,
113f
135, 135f chronic myelomonocytic leukemia
Late myelocyte, and early myelocyte, (CMML), 416–419, 416f lymphoma cells, 113–117
417f 419f mantle cell lymphoma, 526–527,
150, 150f
Late polychromatophilic normoblast, chronic neutrophilic leukemia, 526f 527f
400–402, 400, 400f 402f mucosa-associated lymphoid tissue
and lymphocyte, 143, 143f
LE cell, 86, 86f erythroleukemia (M6a), 381–382, (MALT lymphoma), 522–523,
Lead intoxication (plumbism), 381f 382f 522f 523f
small B lymphoma cell, 117, 117f
224–225, 224f 225f hairy cell leukemia, 513–515, 513f small cleaved lymphoma cell, 116,
Leishmaniasis, 564–565, 564f 565f 515f 116f
Leukemia Lymphopoiesis, 162, 162f
juvenile myelomonocytic leukemia
acute basophilic leukemia, 492–493, ( JMML), 423–425, 423f 425f M
492f 493f
myeloid leukemia associated with Macrocyte
acute erythroid leukemia, 484–488, down syndrome, 497–498, oval, 17, 17f
484f 486f 488f 497f 498f size, 40, 40f

acute megakaryoblastic leukemia, plasma cell leukemia, 519–521, Macrophage, 166, 166f
489–491, 489f 491f 519f 521f Malaria, 52, 52f, 566–567, 566f 567f
Malignant granulocytes, 87–91
acute megakaryoblastic leukemia plasma cell neoplasms, 516–518, Malignant lymphocytes, 107–112
(M7), 385–386, 385f 516f 518f Mantle cell lymphoma, 526–527, 526f

acute monoblastic leukemia precursor lymphoblastic leukemia 527f
(M5a), 377–378, 377f 378f (L1), 387–388, 387f Mast cell, 75, 72f
480–483, 480f 481f 483f Mastocytosis, 412–413, 412f 413f
precursor lymphoblastic leukemia Mature B-cell neoplasms, 508–531
acute monocytic leukemia (M5b), (L2), 389–390, 389f
379–380, 379f 380f B-cell prolymphocytic leukemia,
480–483, 480f 481f 483f pure erythroid leukemia (M6b), 511–512, 511f 512f
383–384, 383f
acute myeloid leukemia without Burkitt lymphoma, 530–531, 530f
maturation (M1), T-cell large granular lymphocytic 531f
365–366, 365f leukemia, 534–535, 534f
535f chronic lymphocytic leukemia/small
acute myeloid leukemia with lymphocytic lymphoma,
maturation (M2), 367–368, 367f T lymphoblastic leukemia/ 508–510, 508f 510f
lymphoma, 504–506, 504f
acute myeloid leukemia, with 506f diffuse large B-cell lymphoma,
minimal differentiation 528–529, 528f 529f
(M0), 363–364, 363f 364f Leukocyte alkaline phosphatase (LAP)
stain, 189–190, 189f follicular lymphoma, 524–525, 524f
acute myelomonocytic leukemia 525f
(M4), 373–374, 373f 374f Leukocyte disorders, nonmalignant,
478–479, 478f 479f 331–356 hairy cell leukemia, 513–515, 513f
515f
acute myelomonocytic leukemia Liver disease, 326–327, 326f 327f
with increased bone Lymphoblast, 99, 99f mantle cell lymphoma, 526–527,
marrow eosinophils (M4eo), Lymphoblastic lymphoma cell, 113, 526f 527f
375–376, 375f
113f mucosa-associated lymphoid tissue
acute promyelocytic leukemia– Lymphocytes, 98–100, 98f (MALT lymphoma), 522–523,
hypergranular (M3), 522f 523f
369–370, 369f late polychromatophilic normoblast
and, 143, 143f plasma cell leukemia, 519–521,
519f 521f
malignant, 107–112
mature, 100, 100f plasma cell neoplasms, 516–518,
monocytes and, 147, 147f 516f 518f
monocytes and reactive, 146, 146f
reactive, 101–106

66485457-66485438 www.ketabpezeshki.com

Index 587

Mature red blood cell (mature Myelocytes, 60–62, 60f 61f 62f Niemann-Pick disease, 578–579, 578f
erythrocyte), 10, 10f early and late, 150, 150f 579f
giant, 93, 93f
May-Hegglin anomaly, 347–348, 347f and myeloblasts, 140, 140f, 141, Nonhematopoietic cells, 171–173,
348f 141f 172f 173f
and promyelocytes, 141, 141f
May-Hegglin inclusion, 82, 82f and pronormoblasts, 148, 148f Nonimmune hemolytic anemia,
Megakaryoblast, 129, 129f 310–311, 310f 311f
Megakaryocyte, 131, 131f Myelodysplastic syndrome with
Megakaryocytes isolated del(5q), 441–443, 441f Nonmalignant leukocyte disorders,
331–356
abnormal megakaryocytic cells, Myelodysplastic syndromes (MDS),
133–137 427–443 basophilia, 332–333, 332f 333f
Chédiak-Higashi anomaly, 334–335,
normal megakaryocytic maturation myelodysplastic syndrome with
series, 128–132 isolated del(5q), 441–443, 334f 335f
441f chronic granulomatous disease,
Megakaryopoiesis, 163, 163f
Megaloblastic anemias, 229–235 refractory anemia with excess 336–337, 336f 337f
blasts (RAEB), 437–440, eosinophilia, 338–339, 338f 339f
folic acid deficiency, 230–232, 230f 437f 438f infectious mononucleosis, 340–341,
232f
refractory anemia with ring 340f 341f
vitamin B12 deficiency, 233–235, sideroblasts (RARS), lymphocytosis, 342–346, 342f 346f
233f 235f 431–433, 431f 432f May-Hegglin anomaly, 347–348,

Megaloblastic maturation series, refractory cytopenia with 347f 348f
11–17, 11f multilineage dysplasia monocytosis, 349–350, 349f 350f
(RCMD), 434–436, 434f neutropenia, 351–352, 351f 352f
basophilic megaloblast neutrophilia, 353–354, 353f 354f
(megaloblastic prorubricyte), refractory cytopenia with Pelger-Huët anomaly, 355–356,
13, 13f unilineage dysplasia
(RCUD), 428–430, 428f 430f 355f 356f
megalocyte (oval macrocyte), 17, 17f Nuclear segmentation, 73–76
orthochromic megaloblast Myelodysplastic/myeloproliferative
neoplasms, 415–425 O
(megaloblastic
metarubricyte), 15, 15f atypical chronic myeloid leukemia Orthochromic megaloblast
polychromatophilic megaloblast (aCML), 420–422, 420f 422f (megaloblastic metarubricyte),
(megaloblastic rubricyte), 15, 15f
14, 14f chronic myelomonocytic leukemia
polychromatophilic megalocyte (CMML), 416–419, 416f Orthochromic normoblast
(megaloblastic reticulocyte), 417f 419f (metarubricyte), 8, 8f
16, 16f
promegaloblast (megaloblastic juvenile myelomonocytic leukemia Osteoblast, 172, 172f
rubriblast), 12, 12f ( JMML), 423–425, 423f, Osteoclast, 173, 173f
Megalocyte (oval macrocyte), 17, 17f 425f Ovalocyte (elliptocyte), 35, 35f
Metamyelocytes, 63–65, 63f 64f 65f
giant, 93, 93f Myeloid leukemia associated with P
neutrophilic bands, and down syndrome, 497–498,
neutrophils, 151, 151f 497f 498f Pappenheimer body, 53, 53f
Microangiopathic hemolytic anemia, Paroxysmal nocturnal
308–309, 308f 309f Myelophthisis, anemia caused by,
Microcyte, 41, 41f 238–239, 238f 239f hemoglobinuria, 312–313,
Micromegakaryocyte, 136, 136f 312f 313f
Microorganisms, 83, 83f Myeloproliferative neoplasms (MPN), Pelger-Huët anomaly, 355–356, 355f
Monoblast, 95, 95f 395–413 356f
and myeloblast, 145, 145f Pelger-Huët cells, 74–75, 74f
and promonocyte, 144, 144f chronic eosinophilic leukemia, Pelgeroid cells, 76, 76f
Monocyte maturation series, 94, 94f 409–411, 409f Periodic acid-Schiff (PAS) reaction,
Monocytes, 94–97, 94f 95f 96f 97f 192–193, 192f
and lymphocytes, 147, 147f chronic myelogenous leukemia, Peroxidase (POX) stain, 194–195,
and reactive lymphocyte, 146, 146f 396–399, 397f 194f
Monocytosis, 349–350, 349f 350f Plasma cell leukemia, 519–521, 519f
Mott cell (grape cell), 125, 125f chronic neutrophilic leukemia, 521f
Mucopolysaccharidosis, 576–577, 400–402, 400, 400f 402f Plasma cell neoplasms, 516–518, 516f
576f 577f 518f
Mucosa-associated lymphoid tissue essential thrombocythemia (ET), Plasma cells, 118–121, 118f 121f
(MALT lymphoma), 522–523, 406–408, 406f 408f abnormal plasma cells and
522f 523f
Myeloblast, 58, 58f 87–89, 87f 88f primary myelofibrosis (PMF), inclusions, 122–126
89f 403–405, 403f 405f Plasmablast, 119, 119f
and basophilic normoblast, 142, Plasmacytes, 118–121
142f N Plasmacytoid lymphocyte, 106, 106f
and monoblast, 145, 145f Platelet disorder, quantitative, 545–551
and myelocytes, 140, 140f, 141, Neutropenia, 351–352, 351f 352f Platelets, 132, 132f
141f Neutrophilia, 353–354, 353f 354f
and promyelocytes, 141, 141f Neutrophilic band, 66, 66f giant, 133, 133f
Plumbism, 224–225, 224f 225f
neutrophils, and metamyelocytes, Polychromatophilic cells, 44, 44f
151, 151f Polychromatophilic erythrocyte

Neutrophilic metamyelocyte, (reticulocyte), 9, 9f
63, 63f

Neutrophilic myelocyte, 60, 60f
Neutrophils, 56, 56f

neutrophilic bands, and
metamyelocytes, 151, 151f

Niemann-Pick cell, 169, 169f

66485457-66485438 www.ketabpezeshki.com

588 Index

Polychromatophilic megaloblast hypoproliferative anemias, 237–251 Spherocyte, 38, 38f
(megaloblastic rubricyte), 14, 14f megaloblastic anemias, 229–235 Spherocytosis, hereditary, 302–303,
Red blood cells
Polychromatophilic megalocyte abnormal maturation, 54 302f 303f
(megaloblastic reticulocyte), agglutination, 25, 25f Stomatocyte, 39, 39f
16, 16f coloring, 42–44 Stomatocytosis, hereditary, 304–305,
distribution, 25–26
Polychromatophilic normoblast erythrocyte series, 4, 4f 304f 305f
(rubricyte), 7, 7f inclusions, 45–53 Sudan black B (SBB) stain, 196–197,
iron-deficient maturation series,
Polycythemia vera, 206–208, 206f 196f
208f 18–24, 18f Systemic disorders, anemias
megaloblastic maturation series,
Polymorphonuclear neutrophil, 69, 69f associated with, 321–329
Precursor lymphoblastic leukemia 11–17, 11f chronic renal disease, 332–323,
normal maturation series, 4–10
(L1), 387–388, 387f rouleaux, 26, 26f 322f 323f
Precursor lymphoblastic leukemia shapes, 27–39 endocrine diseases, 324–325, 324f
size, 40–41
(L2), 389–390, 389f Reed-Sternberg cell, 114, 114f 325f
Precursor lymphoid neoplasms, Refractory anemia with excess blasts liver disease, 326–327, 326f 327f
systemic lupus erythematosus,
499–503 (RAEB), 437–440, 437f 438f
B lymphoblastic leukemia/ Refractory anemia with ring sideroblasts 328–329, 328f 329f
Systemic lupus erythematosus,
lymphoma, 500–503, 500f (RARS), 431–433, 431f 432f
501f 503f Refractory cytopenia with 328–329, 328f 329f
T lymphoblastic leukemia/
lymphoma, 504–506, 504f multilineage dysplasia (RCMD), T
506f 434–436, 434f
Primary myelofibrosis (PMF), Refractory cytopenia with unilineage T-cell large granular lymphocytic
403–405, 403f, 405f dysplasia (RCUD), 428–430, leukemia, 534–535, 534f 535f
Prolymphocyte, 112, 112f 428f 430f
Promegakaryocyte, 130, 130f Relative polycythemia (Gaisböck T lymphoblastic leukemia/lymphoma,
Promegaloblast (megaloblastic Syndrome), 209–210, 209f 210f 504–506, 504f 506f
rubriblast), 12, 12f Reticulin stain, 201, 201f
Promonocyte, 96, 96f Reticuloendothelial system, cells of Tartrate inhibition (TRAP)
Promyelocyte, 59, 59f abnormal cells, 168–170, 168f acid phosphatase reaction with,
and pronormoblast, 149, 149f 176–177, 176f
abnormal, 90–91, 90f 169f 170f acid phosphatase reaction without,
myeloblasts, and myelocytes, 141, normal cells, 166–167, 166f 167f 178, 178f
141f Reticuloendothelial system storage
Pronormoblast (rubriblast), 5, 5f Terminal deoxynucleotidyl transferase
Proplasmacyte, 120, 120f disorders, 573 (TdT) reaction, 198–199, 198f
Pure erythroid leukemia (M6b), Gaucher disease, 574–575, 574f
383–384, 383f a Thalassemia (3 gene deletion-
Pure red cell aplasia, 250–251, 250f 575f hemoglobin H disease),
251f mucopolysaccharidosis, 576–577, 256–257, 256f 257f
Pyknocyte (blister cell), 36, 36f
Pyruvate kinase deficiency, 314–315, 576f 577f a Thalassemia (4 gene deletion),
314f 315f Niemann-Pick disease, 578–579, 254–255, 254f 255f

Q 578f 579f a Thalassemia minor and silent
sea-blue histiocytosis, 580–581, carrier, 258–259, 258f 259f
Quantitative platelet disorders, 545–551
thrombocytopenia, 546–548, 546f 580f 581f b Thalassemia, 260–263, 260f 261f
548f Reticulum cell, 167, 167f 263f
thrombocytosis, 549–551, 549f Rouleaux, 26, 26f
551f Russell bodies, 126, 126f Toluidine blue stain, 200, 200f
Toxic granulation, 84, 84f
R S Toxoplasmosis, 568–569, 568f 569f
Trypanosomiasis, 570–571, 570f 571f
Reactive lymphocytes, 101–106 Schistocyte (Schizocyte), 37, 37f Type I myeloblast, 87, 87f
and monocytes, 146, 146f Sea-blue histiocyte, 170, 170f Type II myeloblast, 88, 88f
reactive (atypical) lymphocytes, Sea-blue histiocytosis, 580–581, 580f Type III myeloblast, 89, 89f
101, 101f
581f U
Red blood cell disorders Secondary polycythemia, 211–212,
acute blood loss, 317–319 Unstable hemoglobins, 288–289, 288f
anemias associated with systemic 211f 212f 289f
disorders, 321–329 Segmented neutrophil
anemias due to disordered iron V
metabolism or heme (polymorphonuclear
synthesis, 213–228 neutrophil), 69, 69f Vacuolated megakaryocyte, 137, 137f
erythrocytosis, 205–212 Sézary cell, 115, 115f Vacuolization, 85, 85f
hemoglobinopathies, 253–289 Sézary syndrome, 538–539, 538f 539f Vitamin B12 deficiency, 233–235, 233f
hemolytic anemias, 291–315 Sideroblastic anemia, 226–228, 226f
228f 235f
Small B lymphoma cell, 117, 117f
Small cleaved lymphoma cell, 116, W
116f
White blood cell disorders
acute myeloid leukemia (AML)
(WHO), 445–498
French American British (FAB)
classification, of leukemia,
357–392

66485457-66485438 www.ketabpezeshki.com

Index 589

Hodgkin lymphoma, 541–543, 542f World Health Organization lymphoma cells, 113–117
543f (WHO) classification, of malignant granulocytes, 87–91
hematologic neoplasms, malignant lymphocytes, 107–112
mature B-cell neoplasms, 507–531 393–394 monocyte maturation series, 94–97,
mature T- and NK-cell neoplasms,
White blood cells 94f
533–539 abnormal maturation, 92–93 neutrophilic series, 56, 56f
myelodysplastic syndromes (MDS), abnormal plasma cells and normal granulocytic maturation
inclusions, 122–126
427–443 basophilic myelocyte, 62–72 series, 56–61
myelodysplastic/myeloproliferative basophilic series, 57, 57f nuclear segmentation, 73–76
cytoplasmic inclusions, plasma cell series, 118–121,
neoplasms, 415–425 77–86
myeloproliferative neoplasms, eosinophilic series, 57, 57f 118f
lymphocyte maturation series, reactive lymphocytes, 101–106
395–413 98–100, 98f World Health Organization (WHO)
nonmalignant leukocyte disorders,
classification, of hematologic
331–356 neoplasms, 393–394
precursor lymphoid neoplasms,

499–503

66485457-66485438 www.ketabpezeshki.com

66485457-66485438 www.ketabpezeshki.com